Mesothelioma Research | Science Advisory Board | Lee Krug, MD,
The Meso Foundation Science Advisory Board: Lee Krug, MD, Chair
The Meso Foundation’s Science Advisory Board strives to be a source of change and hope for mesothelioma patients and their families. Constituted of world-renowned mesothelioma experts, our goal is to help find and advance the leading mesothelioma and asbestos research projects. Additionally, our objective is to continue to provide educational information and resources to patients and healthcare providers about the latest advances in mesothelioma research.
Chairing our board of mesothelioma and asbestos research experts is Dr. Lee Krug.
Meet Lee Krug, MD, Chair
Lee M. Krug, MD, is an Associate Attending Physician in the Division of Thoracic Oncology, Department of Medicine at Memorial Sloan-Kettering Cancer Center in New York, New York where he completed a fellowship and chief fellowship in medical oncology. Dr. Krug is the Director of the Mesothelioma Program at Memorial Sloan-Kettering Cancer Center.
Dr. Krug has investigated multimodality mesothelioma treatment approaches for patients with early stage malignant pleural mesothelioma. He led a multicenter U.S. trial of induction chemotherapy before extrapleural pneumonectomy, and he has a current study testing the feasibility of chemotherapy followed by pleural radiation. Dr. Krug also has a strong interest in novel therapeutics for patients with more advanced disease. He conducted a phase I trial with a WT-1 peptide vaccine, and he was awarded a grant from the Department of Defense to conduct a randomized phase II trial with this vaccine. He is also the principal investigator of an international, phase III trial of a histone deacetylase inhibitor, vorinostat. Dr. Krug led the committee for the National Comprehensive Cancer Network (NCCN) that established treatment guidelines for mesothelioma. He is the chairman of the Scientific Advisory Board at the Meso Foundation and also serves on the Board of Directors.
Lee Krug, MD Contact Info: